• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® TAG® THORACIC BRANCH ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® TAG® THORACIC BRANCH ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Model Number TAC123415A
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code Stroke/CVA (1770)
Date of Event 12/23/2022
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Additional devices included on this report are as follows: catalog #tsb121506a/ serial #(b)(4)/ udi #(b)(4) as the same system of components.Catalog #tgm343410,serial (b)(4), udi (b)(4), catalog #tgm343420, serial (b)(4), udi (b)(4), catalog #bcm1634, serial (b)(4),udi (b)(4).Patient weight: asked but unavailable.Other relevant history, including preexisting medical conditions: asked but unavailable.As the gore® tag® thoracic branch side branch is a combination product, applies to this device.Name: cbas® heparin surface.Manufacturer/compounder: w.L.Gore & associates, inc.Lot number: 25644801.Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.Concomitant medical products and therapy dates: asked but unavailable.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Event or Problem Description
On (b)(6) 2022, the patient underwent endovascular treatment of a zone 0 thoracic aortic aneurysm using gore® tag® thoracic branch endoprostheses.It was noted that the patient's anatomy was extremely tortuous.It was reported that the patient experienced a stroke post procedure.The physician also noted that it may have occurred intra procedure.Reportedly the cause of the stroke is unknown, but it was suspected to be related to wire and device manipulation.Due to the anatomical tortuosity, there was also difficulty reported while attempting to align the portal of the thoracic branch aortic component to the outer curve in aortic zone 0.It was reported that the patient remained in the hospital post procedure for stroke complications including aphasia.On (b)(6) 2023, the physician reported that the patient's aphasia was significantly improved, and the patient was walking with the physical therapist.The patient was reportedly discharged to home on or about (b)(6) 2022.
 
Additional Manufacturer Narrative
H.6.Investigation findings: code c19 - the review of the manufacturing paperwork verified that the lots involved in this event met all pre-release specifications.H.6.Investigation conclusions: code d12 added.According to the gore® tag® thoracic branch endoprosthesis instructions for use, potential adverse events and complications that may occur with the use of the gore® tag® thoracic branch endoprosthesis include, but are not limited to, neurologic damage, local or systemic (e.G., stroke, paraplegia, paraparesis).H.6.Investigation findings for analysis of production records: code c21 updated to code c19.H.6.Investigation conclusions: code d16 updated to code d15.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® TAG® THORACIC BRANCH ENDOPROSTHESIS
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL WOODY SPRINGS B/P
3450 w. kiltie lane
flagstaff AZ 86005
Manufacturer Contact
jenna lopez
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key16221805
Report Number2017233-2023-03657
Device Sequence Number17511186
Product Code MIH
UDI-Device Identifier00733132654192
UDI-Public00733132654192
Combination Product (Y/N)N
Initial Reporter StateCO
Initial Reporter CountryUS
PMA/510(K) Number
P210032
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2022
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Company Representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 03/28/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date07/18/2024
Device Model NumberTAC123415A
Device Catalogue NumberTAC123415A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 12/23/2022
Supplement Date Received by Manufacturer02/28/2023
Initial Report FDA Received Date01/22/2023
Supplement Report FDA Received Date03/28/2023
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured07/20/2021
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Other;
Patient Age78 YR
Patient SexFemale
-
-